Amphastar Pharmaceuticals (AMPH) Set to Announce Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.8640 per share and revenue of $197.52 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. On average, analysts expect Amphastar Pharmaceuticals to post $2.43 EPS for the current fiscal year and $2.55 EPS for the next fiscal year.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $26.33 on Thursday. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 4.84 and a beta of 0.90. Amphastar Pharmaceuticals has a 12 month low of $16.65 and a 12 month high of $29.52. The firm has a fifty day simple moving average of $24.54 and a 200 day simple moving average of $22.32. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on AMPH shares. Wells Fargo & Company lifted their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 24th. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 16th. Finally, Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $22.50.

Insiders Place Their Bets

In other news, Director Richard K. Prins sold 7,973 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the completion of the sale, the director owned 29,625 shares of the company’s stock, valued at approximately $601,387.50. This represents a 21.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Rong Zhou sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the transaction, the executive vice president directly owned 169,203 shares of the company’s stock, valued at $4,050,719.82. This represents a 5.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 33,479 shares of company stock valued at $763,922 in the last 90 days. 29.60% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.